scPharmaceuticals (SCPH) Competitors $3.35 +0.15 (+4.69%) Closing price 02/4/2025 04:00 PM EasternExtended Trading$3.36 +0.00 (+0.15%) As of 02/4/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SCPH vs. BCAX, CRGX, DNTH, KURA, PHAR, TECX, IMNM, AUTL, CGEM, and HUMAShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Bicara Therapeutics (BCAX), CARGO Therapeutics (CRGX), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), Pharming Group (PHAR), Tectonic Therapeutic (TECX), Immunome (IMNM), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Bicara Therapeutics CARGO Therapeutics Dianthus Therapeutics Kura Oncology Pharming Group Tectonic Therapeutic Immunome Autolus Therapeutics Cullinan Therapeutics Humacyte scPharmaceuticals (NASDAQ:SCPH) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings. Do analysts rate SCPH or BCAX? scPharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 347.76%. Bicara Therapeutics has a consensus price target of $43.75, indicating a potential upside of 257.43%. Given scPharmaceuticals' higher possible upside, equities research analysts clearly believe scPharmaceuticals is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media refer more to SCPH or BCAX? In the previous week, Bicara Therapeutics had 4 more articles in the media than scPharmaceuticals. MarketBeat recorded 4 mentions for Bicara Therapeutics and 0 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 1.87 beat Bicara Therapeutics' score of 0.38 indicating that scPharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment scPharmaceuticals Very Positive Bicara Therapeutics Neutral Does the MarketBeat Community favor SCPH or BCAX? scPharmaceuticals received 152 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 66.67% of users gave scPharmaceuticals an outperform vote. CompanyUnderperformOutperformscPharmaceuticalsOutperform Votes16066.67% Underperform Votes8033.33% Bicara TherapeuticsOutperform Votes8100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in SCPH or BCAX? 89.5% of scPharmaceuticals shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, SCPH or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than scPharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$13.59M12.34-$54.81M-$1.90-1.76Bicara TherapeuticsN/AN/AN/AN/AN/A Is SCPH or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. Bicara Therapeutics' return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-264.60% -244.93% -68.56% Bicara Therapeutics N/A N/A N/A SummaryBicara Therapeutics beats scPharmaceuticals on 8 of the 14 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.63M$6.88B$5.67B$9.12BDividend YieldN/A2.88%5.28%4.00%P/E Ratio-1.769.9788.1618.30Price / Sales12.34318.731,082.4377.21Price / CashN/A22.6637.4433.55Price / Book3.225.305.124.76Net Income-$54.81M$125.74M$108.98M$223.10M7 Day Performance2.45%0.65%0.67%-0.11%1 Month Performance-6.69%-4.85%-0.88%-1.99%1 Year Performance-31.77%10.45%26.16%21.66% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.1884 of 5 stars$3.35+4.7%$15.00+347.8%-31.8%$167.63M$13.59M-1.7630Positive NewsBCAXBicara TherapeuticsN/A$11.65+0.3%$43.75+275.5%N/A$633.99MN/A0.0032Upcoming EarningsGap UpCRGXCARGO Therapeutics3.204 of 5 stars$13.66+1.5%$31.80+132.8%-84.3%$628.77MN/A-3.21116Analyst RevisionNews CoverageDNTHDianthus Therapeutics2.1671 of 5 stars$21.10-0.5%$46.43+120.0%+10.3%$624.56M$2.83M-8.4480Short Interest ↑News CoverageKURAKura Oncology4.7065 of 5 stars$7.91-0.9%$27.38+246.1%-57.9%$615.08MN/A-3.35130PHARPharming Group2.9276 of 5 stars$9.00-1.1%$27.00+200.0%-34.0%$610.52M$285.75M-34.62280Gap UpTECXTectonic Therapeutic2.3454 of 5 stars$41.18-11.9%$72.25+75.4%N/A$607.53MN/A-6.99120News CoverageGap DownIMNMImmunome1.7126 of 5 stars$9.69-2.6%$28.83+197.6%-32.0%$604.85M$14.02M-1.1940Insider TradeShort Interest ↑News CoverageGap UpAUTLAutolus Therapeutics3.1123 of 5 stars$2.26-4.9%$10.40+361.2%-64.0%$600.03M$1.70M-1.86330Short Interest ↑CGEMCullinan Therapeutics2.5219 of 5 stars$10.30-2.4%$31.67+207.4%-42.5%$599.77MN/A-3.6330Analyst RevisionHUMAHumacyte3.353 of 5 stars$4.51-2.2%$13.71+204.1%+32.4%$567.62M$1.57M-3.37150Short Interest ↓ Related Companies and Tools Related Companies Bicara Therapeutics Alternatives CARGO Therapeutics Alternatives Dianthus Therapeutics Alternatives Kura Oncology Alternatives Pharming Group Alternatives Tectonic Therapeutic Alternatives Immunome Alternatives Autolus Therapeutics Alternatives Cullinan Therapeutics Alternatives Humacyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPH) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
